Bendamustine Plus Rituximab Versus CHOP Plus Rituximab

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2009
The study addresses the question if the first line therapy of low malignant and mantle cell lymphomas with bendamustine plus rituximab is comparable (non inferior) with CHOP plus rituximab with regard to progression free survival (PFS).
Epistemonikos ID: 1071977bce19d1f829d84af73c56e45ac33f3f0d
First added on: Jan 21, 2022